Abstract
Background
The response rate of advanced or recurrent gastric cancer to S-1 (TS-1®) is 46.5%, which is higher than the response rate of this type of cancer to any other anticancer agent. However, the incidence of adverse reactions to this drug has also been reported to be as high as 83.2%. According to a postmarketing survey, adverse reactions to this drug begin to appear 2–3 weeks after the start of drug administration. With these findings in mind, we recently devised a new dosing regimen for the drug, by which the drug is administered for 2-week periods separated by 1-week drug-free intervals (the 2-week regimen). The aim of this retrospective study was to evaluate the efficacy and feasibility of the 2-week regimen in comparison with a 4-week dosing regimen with a 2-week interval between sessions (the 4-week regimen) as the historical control.
Methods
The subjects were 27 patients with advanced or recurrent gastric cancer who received S-1 therapy at our center between September 1999 and November 2001. Of these patients, 14 who received the 4-week regimen before January 2001 served as historical controls, and the results in these patients were compared with those of the remaining 13 patients, who received the 2-week regimen after February 2001. Patient backgrounds, adverse reactions, compliance, and efficacy were investigated retrospectively.
Results
The incidence of adverse reactions tended to be lower in the 2-week-regimen group (77%) than in the 4-week-regimen group (93%). The percentage of patients who received the drug for 6 months in complete compliance with the dosing schedule, as calculated by the Kaplan-Meier method, was 85% in the 2-week-regimen group and 40% in the 4-week-regimen group. The response rate to the drug was 23% in the 2-week-regimen group and 21% in the 4-week-regimen group.
Conclusion
These results suggest that this 2-week regimen may mitigate adverse reactions and prolong the medication period.
Article PDF
Similar content being viewed by others
References
R Duschinsky E Pleven C Heidelberger (1957) ArticleTitleThe synthesis of 5-fluoropyrimidines J Am Chem Soc Anticancer 79 4559–60 Occurrence Handle1:CAS:528:DyaG1cXitFWgug%3D%3D
GA Caballero RK Ausman EJ Quebbeman (1985) ArticleTitleLong-term ambulatory continuous iv infusion of 5-FU for the treatment of advanced adenocarcinomas Cancer Treat Rep 69 13–15 Occurrence Handle3155649 Occurrence Handle1:STN:280:BiqD1MbhsVY%3D
T Moynihan R Hansen T Anderson E Quebbeman P Beatty R Ausman et al. (1988) ArticleTitleContinuous 5-fluorouracil infusion in advanced gastric carcinoma Am J Clin Oncol 11 461–4 Occurrence Handle3407626 Occurrence Handle1:STN:280:BieA3cjjt1E%3D
E Quebbeman R Ausman R Hansen T Becker G Caballero P Ritch et al. (1985) ArticleTitleLong-term ambulatory treatment of metastatic colorectal adenocarcinoma by continuous intravenous infusion of 5-fluorouracil J Surg Oncol 30 60–5 Occurrence Handle3935873 Occurrence Handle1:STN:280:BimD1M%2FlsVM%3D
JJ Lokich JD Ahlgren JJ Gullo JA Philips JG Freyer (1989) ArticleTitleA prospective randomized comparison of continuous infusion fluorouracil with a conventional bolus schedule in metastatic colorectal carcinoma: a Mid-Atlantic Oncology Program Study J Clin Oncol 7 425–32 Occurrence Handle2926468 Occurrence Handle1:STN:280:BiaC2sjkt1c%3D
T Shirasaka Y Shimamoto H Ohshimo M Yamaguchi T Kato K Yonekura et al. (1996) ArticleTitleDevelopment of a novel form of an oral 5-fluorouracil derivative (S-1) directed to the potentiation of the tumor selective cytotoxicity of 5-fluorouracil by two biochemical modulators Anticancer Drugs 7 548–57 Occurrence Handle8862723 Occurrence Handle1:CAS:528:DyaK28Xltleru78%3D
T Shirasaka K Nakano T Takechi H Satake J Uchida A Fujioka et al. (1996) ArticleTitleAntitumor activity of 1 M tegafur-0.4 M 5-chloro-2,4-dihydroxypyridine-1 M potassium oxonate (S-1) against human colon carcinoma orthotopically implanted into nude rats Cancer Res 56 2602–6 Occurrence Handle8653704 Occurrence Handle1:CAS:528:DyaK28XjtlCgurg%3D
K Tatsumi M Fukushima T Shirasaka S Fujii (1987) ArticleTitleInhibitory effects of pyrimidine, barbituric acid and pyridine derivatives on 5-fluorouracil degradation in rat liver extracts Jpn J Cancer Res 78 748–55 Occurrence Handle3114201 Occurrence Handle1:CAS:528:DyaL2sXlvFSntL8%3D
T Shirasaka Y Shimamoto M Fukushima (1993) ArticleTitleInhibition by oxonic acid of gastrointestinal toxicity of 5-fluorouracil without loss of its antitumor activity in rats Cancer Res 53 4004–9 Occurrence Handle7689420 Occurrence Handle1:CAS:528:DyaK3sXmtFKqsrk%3D
RB Diasio (1999) ArticleTitleClinical implications of dihydropyrimidine dehydrogenase Oncology 13 IssueID7 Suppl 3 17–21 Occurrence Handle10442353 Occurrence Handle1:STN:280:DyaK1MzntV2nsw%3D%3D
K Hirata N Horikoshi K Aiba M Okazaki R Denno K Sasaki et al. (1999) ArticleTitlePharmacokinetic study of S-1, a novel oral fluorouracil antitumor drug Clin Cancer Res 5 2000–5 Occurrence Handle10473078 Occurrence Handle1:STN:280:DyaK1MvgtVSmtQ%3D%3D
Y Sakata A Ohtsu N Horikoshi K Sugimachi Y Mitachi T Taguchi (1998) ArticleTitleLate phase II study of novel fluoropyrimidine anticancer drug S-1 (1 M tegafur-0.4 M gimestat-1 M otastat potassium) in advanced gastric cancer patients Eur J Cancer 34 1715–20 Occurrence Handle9893658 Occurrence Handle10.1016/S0959-8049(98)00211-1 Occurrence Handle1:CAS:528:DyaK1cXntlShurw%3D
K Sugimachi Y Maehara N Horikoshi Y Shimada Y Sakata Y Mitachi et al. (1999) ArticleTitleAn early phase II study of oral S-1, a newly developed 5-fluorouracil derivative for advanced and recurrent gastrointestinal cancers Oncology 57 202–10 Occurrence Handle10545788 Occurrence Handle10.1159/000012032 Occurrence Handle1:CAS:528:DyaK1MXmvF2msr0%3D
http://www.taiho.co.jp/gan-net/ts-1/anzen/index.html
P Therasse SG Arbuck EA Eisenhauer J Wanders RS Kaplan L Rubinstein et al. (2000) ArticleTitleNew guidelines to evaluate the response to treatment in solid tumors J Nat Cancer Inst 92 205–16 Occurrence Handle10655437 Occurrence Handle10.1093/jnci/92.3.205 Occurrence Handle1:STN:280:DC%2BD3c7it1Gitg%3D%3D
Japanese Research (1995) Society for Gastric Cancer. Response assessment of chemotherapy for gastric carcinoma. Japanese classification of gastric carcinoma EditionNumber1st English Ed. Kanehara Tokyo 90–104
K Ota T Taguti K Kimura (1988) ArticleTitleReport on nationwide pooled data and cohort investigation in UFT phase II study Cancer Chemother Pharmacol 22 333–8 Occurrence Handle3139315 Occurrence Handle10.1007/BF00254241 Occurrence Handle1:STN:280:BiaD3czktVI%3D
H Niitani K Kimura T Saito I Nakao O Abe I Urushizaki et al. (1985) ArticleTitlePhase II study of 5′-deoxy-5-fluorouridine(5′-DFUR) on patients with malignant cancer: multi-institutional cooperative study Jpn J Cancer Chemother 12 2044–51 Occurrence Handle1:STN:280:BimD38vjt1w%3D
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Kimura, Y., Kikkawa, N., Iijima, S. et al. A new regimen for S-1 therapy aiming at adverse reaction mitigation and prolonged medication by introducing a 1-week drug-free interval after each 2-week dosing session: efficacy and feasibility in clinical practice. Gastric Cancer 6 (Suppl 1), 34–39 (2003). https://doi.org/10.1007/s10120-003-0230-y
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/s10120-003-0230-y